Gretchen Gignac | Profiles RNS

Gretchen Gignac, MD

Clinical Associate Professor

Boston University Chobanian & Avedisian School of Medicine

Medicine

Hematology & Medical Oncology

MD, University of Pennsylvania School of Medicine
BA, University of Rochester

Websites

	Boston Medical Center Provider Profile
	ResearchGate

ORCID : 0000-0001-8532-9558

I am a medical oncologist who has clinical and research expertise in genitourinary medical oncology as well as clinical trials. My clinical practice is at Boston Medical Center and includes adult patients with cancers of the prostate, kidney, bladder, testicles and penis, as well as other solid cancers. My treatment expertise is in hormonal agents, chemotherapy, immunotherapy, targeted therapies, radioactive pharmaceuticals, bone targeted therapies, supportive and palliative care. I am also an educator in the Chobanian and Avedisian School of Medicine and Boston Medical Center Hematology and Oncology Fellowship Program.

Diversity, Equity, Inclusion and Accessibility

I am committed to promoting diversity and inclusion in academia and medicine. I am a part of a dedicated team of healthcare professionals, researchers, students and staff that serves the communities of Boston and its surroundings. I have great pride working at a large academic medical center and safety-net hospital that shares my goal to provide equitable cutting edge clinical care and research opportunities to our patients. I am dedicated to continuing research, clinical and career mentorship for trainees at all levels at Chobanian and Avedisian School of Medicine and Boston Medical Center. My clinical research is focused on improving equity in prostate cancer care and these initiatives have been supported through grant funded research (e.g. DOD and NIH) and have resulted in peer reviewed publications.

Member
Boston University
BU-BMC Cancer Center

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research

BU Research
BMC Research

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 11/16/2015 (PI)
Millennium Pharmaceuticals, Inc.

A Randomized phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen to Cabazitaxel/Prednisone for second line chemotherapy in men with metastatic castrte resistant prostate cance
09/28/2012 - 08/13/2015 (PI)
OncoGenex Technologies, Inc

A phase 3, Randomized, Double-blind, controlled study of cabozantinib (XL184) vs. Prednisone in Metastatic castration resistant prostate cancer patients who have received prior cocetaxel and prior abi
10/19/2012 - 10/19/2014 (PI)
Exelixis, Inc

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.

DFCI 21-575 - A Phase 2 study of avelumab, axitinib and palbociclib in metastatic renal cell carcinoma
03/21/2022 - 03/20/2024 (PI)
Dana Farber Cancer Institute

Precision Interception of Aggressive Prostate Cancer in African American Men
09/18/2018 - 08/31/2022 (Subcontract PI)
PI: Gretchen Gignac, MD
Dana Farber Cancer Institute NIH NCI
5P20CA233255-03

CA209-9KD-070
12/03/2018 - 12/03/2021 (PI)
Bristol-Myers Squibb Company

SGN22E-003: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
10/02/2020 - 10/01/2021 (PI)
Seattle Genetics, Inc.

Racial Differences in Androgen Receptor Splice Variants in Men with Localized Prostate Cancer
03/01/2018 - 05/31/2021 (Subcontract PI)
PI: Gretchen Gignac, MD
The General Hospital Corporation / MGH Dept of Defense

Title

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Beidler LB, Zayhowski K, Nahorniak M, Loo S, Gignac GA, Wang C, Gunn CM. Perceptions and Use of Germline Genetic Testing Among Patients With Prostate Cancer. JCO Oncol Pract. 2025 Mar 03; OP2400624.View Related Profiles.

Wang, Catharine
Gignac, Gretchen
Zayhowski, Kimberly

PMID: 40030090; DOI: 10.1200/OP-24-00624;

Zayhowski K, Wang C, Nahorniak M, Loo S, Gignac G, Gunn C. A qualitative study of the experiences of patients with prostate cancer when receiving negative genetic results: "I still don't have a grasp of what it all means". J Genet Couns. 2024 Nov 29.View Related Profiles.

Wang, Catharine
Gunn, Christine
Gignac, Gretchen
Zayhowski, Kimberly

PMID: 39611226; DOI: 10.1002/jgc4.2003;

Khosla H, Bhatt S, Wang MJ, Gignac G, Mittal K, Patel J. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis. J Oncol Pharm Pract. 2024 Jul; 30(5):941-944. PMID: 38470473

Gunn CM, Gignac G, Hardy B, Zayhowski K, Pankowska M, Loo S, Wang C. Characterizing Referrals for Prostate Cancer Genetic Services in a Safety-Net Hospital. JCO Oncol Pract. 2023 Oct; 19(10):852-859.View Related Profiles.

Wang, Catharine
Gunn, Christine
Gignac, Gretchen
Zayhowski, Kimberly

PMID: 37384869; DOI: 10.1200/OP.23.00055;

Gunn CM, Li EX, Gignac GA, Pankowska M, Loo S, Zayhowski K, Wang C. Delivering Genetic Testing for Patients with Prostate Cancer: Moving Beyond Provider Knowledge as a Barrier to Care. Cancer Control. 2023; 30:10732748221143884.View Related Profiles.

Wang, Catharine
Gunn, Christine
Gignac, Gretchen
Zayhowski, Kimberly

PMID: 36946278; PMCID: PMC10037728; DOI: 10.1177/10732748221143884;

Jafari N, Chen A, Kolla M, Pompa IR, Qiu Y, Yu R, Llevenes P, Ennis CS, Mori J, Mahdaviani K, Halpin M, Gignac GA, Heaphy CM, Monti S, Denis GV. Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. Adv Cancer Biol Metastasis. 2022 Dec; 6.View Related Profiles.

Heaphy, Christopher
Denis, Gerald
Gignac, Gretchen
Mori, Joakin
Mahdaviani, Kiana
Halpin, Meredith
Jafari, Naser
Monti, Stefano

PMID: 36644690; PMCID: PMC9836031; DOI: 10.1016/j.adcanc.2022.100073;

Quintiliani LM, Murray GF, Waite K, Salerno K, Gignac GA, Yuh D, Volandes A, Paasche-Orlow MK. "I'm in My Feelings Now": Examination of Advance Care Planning Video Declarations by People with Advanced Cancer from a Safety Net Hospital. J Palliat Med. 2023 Jan; 26(1):28-34.View Related Profiles.

Gignac, Gretchen
Quintiliani, Lisa
Paasche-Orlow, Michael

PMID: 35708552

Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate. 2022 Jun; 82(10):1005-1015.View Related Profiles.

Heaphy, Christopher
Denis, Gerald
Gignac, Gretchen
Mori, Joakin
Wisco, Jonathan
Katz, Mark

PMID: 35403746; PMCID: PMC11134172; DOI: 10.1002/pros.24351;

Chua S, Qureshi MM, Boyd G, Gignac GA, Hirsch AE. Outcomes for Young Men With Localized Intermediate-Risk Prostate Cancer: An Analysis of the NCDB. Clin Genitourin Cancer. 2020 10; 18(5):e531-e542.View Related Profiles.

Hirsch, Ariel
Gignac, Gretchen
Qureshi, Muhammad

PMID: 32220567

Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2019 Feb; 21(2):206-212.View Related Profiles.

Gignac, Gretchen
Karantanos, Theodoros

PMID: 29948974

Showing 10 of 24 results. Show More

Kan CK, Qureshi MM, Gupta A, Agarwal A, Gignac GA, Bloch BN, Thoreson N, Hirsch AE. Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):181-189.View Related Profiles.

Hirsch, Ariel
Bloch, Boris
Gignac, Gretchen
Qureshi, Muhammad

PMID: 29904743; PMCID: PMC6000162; DOI: 10.1016/j.adro.2017.12.002;

Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016 Sep; 23(9):691-8.View Related Profiles.

Gignac, Gretchen
Karantanos, Theodoros

PMID: 27515296; DOI: 10.1530/ERC-16-0222;

Gunnarsson O, Basaria S, Gignac GA. Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. Cancers (Basel). 2015; 7(2):679-87. PMID: 25913100; PMCID: PMC4491678; DOI: 10.3390/cancers7020679;

Gunnarsson O, Basaria S, Gignac G. The prevalence of metabolic risk factors in black men with prostate cancer undergoing consideration for androgen-deprivation therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):e15082. PMID: 28020432

Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25.View Related Profiles.

Ozonoff, Alexander
Zumwalt, Ann
Hirsch, Ariel
Wang, David
Gignac, Gretchen
Janicek, Milos
Babayan, Richard

PMID: 24673925; DOI: 10.1016/j.prro.2010.11.007;

Ariel E. Hirsch, John J. Cuaron, Milos J. Janicek, Kit Mui, Richard J. Lee, David S. Wang, Richard K. Babayan, Ann C. Zumwalt, Gretchen A. Gignac, Wen Tao, Alexander Ozonoff, Anthony L. Zietman et al. . Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Practical Radiation Oncology. 2011; 1(2):115-125.

Chi D, Hirsch AE, Gignac GA. Biochemical failure after radiation therapy for prostate cancer: Racial differences. J Clin Oncol. 2009 May 20; 27(15_suppl):e16071.View Related Profiles.

Hirsch, Ariel
Gignac, Gretchen

PMID: 27963037

Dickstein RJ, Kreshover JE, Milose JC, Gignac GA. Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era. J Clin Oncol. 2009 May 20; 27(15_suppl):e16159. PMID: 27963401

Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 May 20; 27(15):2436-42. PMID: 19364960; PMCID: PMC2684850; DOI: 10.1200/JCO.2008.20.4164;

Gignac GA, Morris MJ, Heller G, Schwartz LH, Scher HI. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008 Sep 1; 113(5):966-74. PMID: 18661513; PMCID: PMC2708077; DOI: 10.1002/cncr.23719;

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Dec 1; 13(23):7053-8. PMID: 18056182

Gignac GA, Morris MJ, Hussain M. Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions. J Urol. 2007 Sep; 178(3 Pt 2):S30-5. PMID: 17644121

Gignac GA, Morris MJ, Schwartz LH, Lis E, Scher HI. Magnetic resonance imaging of the bone marrow (MRBM) as an outcome measure for patients with metastatic prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14521. PMID: 27954667

Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Intern Med. 2002 Mar 19; 136(6):463-70. PMID: 11900499

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 24 publications over 15 distinct years, with a maximum of 3 publications in 2009 and 2011 and 2022